Neuphoria Therapeutics (NEUP) Other Non-Current Assets (2021 - 2025)
Neuphoria Therapeutics (NEUP) reported Other Non-Current Assets of $79647.0 for Q4 2025, up 7.66% year-over-year from $73982.0 in Q4 2024, and up 1.38% on a QoQ basis from $78564.0 in Q3 2025.
Neuphoria Therapeutics (NEUP) has 5 years of Other Non-Current Assets data on file, last reported at $79647.0 in Q4 2025.
- Quarterly Other Non-Current Assets rose 7.66% year-over-year to $79647.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $79647.0 (up 7.66% YoY) and the FY2025 annual result came in at $77945.0, down 1.12% from the prior year.
- Other Non-Current Assets grew to $79647.0 in Q4 2025 per NEUP's latest filing, from $78564.0 in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $91636.6 in Q2 2021 and bottomed at $73982.0 in Q4 2024.
- The 5-year median for Other Non-Current Assets is $79180.4 (2023), against an average of $80143.4.
- The widest annual swing landed in 2024, when Other Non-Current Assets slipped 9.11%; it then gained 7.66% in 2025.
- Tracing NEUP's Other Non-Current Assets over 5 years: stood at $91636.6 in 2021, then declined by 6.98% to $85235.9 in 2022, then decreased by 4.51% to $81396.0 in 2023, then fell by 9.11% to $73982.0 in 2024, then climbed by 7.66% to $79647.0 in 2025.
- Per Business Quant, the three latest NEUP Other Non-Current Assets figures stand at $79647.0 (Q4 2025), $78564.0 (Q3 2025), and $77945.0 (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 12.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 60,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.26 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 2.13 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 63.55 Mn |
| 10 | Neuphoria Therapeutics | 28.35 Mn | 8.95 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 79,647.00 |
| Sep 30, 2025 | 78,564.00 |
| Jun 30, 2025 | 77,945.00 |
| Mar 31, 2025 | 74,732.00 |
| Dec 31, 2024 | 73,982.00 |
| Sep 30, 2024 | 82,491.00 |
| Jun 30, 2024 | 78,826.00 |
| Mar 31, 2024 | 77,731.00 |
| Dec 31, 2023 | 81,396.00 |
| Jun 30, 2023 | 79,534.89 |
| Jun 30, 2022 | 85,235.93 |
| Jun 30, 2021 | 91,636.56 |